Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02358473 · ClinicalTrials.gov registry record · Phase 1
Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer
A Phase 1 study of Non-Small Cell Lung Cancer, sponsored by Kyowa Kirin.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 5
- Study locations
NCT02358473 is a Phase 1 study of Non-Small Cell Lung Cancer that has completed, run by Kyowa Kirin. The registered enrollment target is 13 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT02358473, a Phase 1 study of Non-Small Cell Lung Cancer, has completed, sponsored by Kyowa Kirin.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.
Conditions Studied
Interventions
- DRUG Docetaxel
- BIOLOGICAL mogamulizumab
Study Locations (5)
Texas
- MD Anderson - Houston
- Cancer Therapy and Research Center - San Antonio
Indiana
- Horizon Oncology - Lafayette
Maryland
- John Hopkins University School of Medicine - Baltimore
Ohio
- Gabrail Cancer Center Research - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02358473
The ClinicalTrials.gov registry entry for NCT02358473 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Kyowa Kirin, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Docetaxel is the first listed.
NCT02358473 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, Indiana, Maryland.
Frequently Asked Questions
What is clinical trial NCT02358473 about?
NCT02358473 is a clinical study titled "Study of Mogamulizumab + Docetaxel in Subjects With Non-small Cell Lung Cancer". The purpose of this study is to evaluate the safety of mogamulizumab in combination with docetaxel in adult subjects with previously treated locally advanced or metastatic non-small cell lung cancer.
What is the current status of trial NCT02358473?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2015-01. Estimated completion is 2016-12.
What conditions does trial NCT02358473 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT02358473?
The interventions under investigation include: Docetaxel (DRUG), mogamulizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02358473?
This trial is sponsored by Kyowa Kirin, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02358473 being conducted?
This trial has 5 study locations across Indiana, Maryland, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.